Biopharmx (BPMX) Releases Earnings Results

Biopharmx (NYSEAMERICAN:BPMX) issued its earnings results on Thursday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02), Bloomberg Earnings reports.

Shares of BPMX opened at $0.16 on Friday. Biopharmx has a 52-week low of $0.10 and a 52-week high of $0.38.

In other news, Director Stephen Morlock sold 1,125,027 shares of the stock in a transaction on Monday, October 22nd. The stock was sold at an average price of $0.18, for a total transaction of $202,504.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anja B. Krammer sold 500,000 shares of the stock in a transaction on Friday, October 12th. The stock was sold at an average price of $0.19, for a total value of $95,000.00. The disclosure for this sale can be found here.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at

Biopharmx Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Story: Short Selling – Explanation For Shorting Stocks

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.

Leave a Reply